QU researchers discover groundbreaking potential for treating diabetes

Doha, Qatar: Qatar University (QU) has achieved a significant milestone in diabetes treatment research.

Dr. Layla Al Mansoori, Research Assistance Professor at QU’s Biomedical Research Center (BRC), in collaboration with her colleagues, has unveiled a groundbreaking discovery with immense promise for individuals living with diabetes, particularly Type 2.

Their study focuses on the critical role of the protein GATA3 in the development of this chronic health condition.

Diabetes affects millions of people worldwide, with Type 2 diabetes being the most prevalent form. It is characterised by insulin resistance, where the body’s cells are unable to effectively use insulin. This condition results in elevated blood sugar levels, which, over time, can lead to damage to blood vessels, nerves, and organs.

In recent years, researchers worldwide have been diligently working to better comprehend the underlying causes of diabetes and explore novel treatment avenues. QU’s scientific team, led by Dr. Layla Al Mansoori, alongside Dr. Mohamed Elrayess, Associate Research Professor at BRC, and Dr. Hamda Abdulla Al Naemi, Director of the Laboratory Animal Research Center (LARC), embarked on an innovative investigation into GATA3 inhibition and its effects on adipogenesis and insulin signaling.

These groundbreaking findings suggest that modulating GATA3 expression holds the potential for therapeutic benefits by correcting impaired adipogenesis, promoting healthier fat distribution, improving insulin sensitivity, and potentially reducing the risk of Type 2 diabetes.

Moreover, the observed reduction in omental tissue size indicates that inhibiting GATA3 could offer a non-surgical alternative for improved fat distribution, presenting exciting possibilities in the cosmetic industry. The research conducted by Dr. Mohamed Elrayess and Dr. Layla Al Mansoori has been patented at the United States Patent and Trademark Office, with a publication date of December 2021. Recognising the significance of this breakthrough, the office of Strategic Innovation, Entrepreneurship, and Economic Development (SIEED) at QU, in collaboration with the inventors, is actively exploring potential investments from international pharmaceutical companies.

“While further research is necessary to fully comprehend the effects of GATA3 inhibition and determine its therapeutic efficacy for individuals with diabetes, our findings provide a solid foundation for further investigations into the potential benefits of inhibiting GATA3,” stated Dr. Layla Al Mansoori.

“This discovery represents a promising approach to diabetes treatment, with the potential to transform lives and improve patient outcomes.”